The original site for employees in pharma, medical & diagnostic sales. Pharma & biotech news with context, clarity, and a little industry humor.
Joined August 2008
- Tweets 74,035
- Following 293
- Followers 17,499
- Likes 29
140 Photos and videos
Pinned Tweet
Jan 9
We’re running a short, anonymous survey to better understand how those in the industry are using AI today. Results will be shared at a high level with the community. Please let us know your thoughts here: forms.gle/8xPdatew4hDh8Kxk9
1
2
1,086
Tue news: Novo races for China launch of Wegovy pill. How Biogen is transforming. Big Pharma's 10 highest-paid CEOs of 2025. FDA starts kicks off review of Gilead's weekly HIV pill. —bit.ly/3JeBlY5
108
Jun 15
Mon news: AZ's Truqap and Roche assay cleared for PTEN prostate cancer. Sanofi wins T1D nod for Tzield. Lilly oncology chief blown away by new Jaypirca CLL data. Lundbeck drug delivers in Cushing syndrome —bit.ly/3JeBlY5
161
Jun 12
Fri news: Biotech IPOs here to stay after another record-breaking listing. Drugmakers will not be exempt from cost cuts, says German health minister. Jazz Pharma misses lung cancer trial endpoint. Is medtech hungry for M&A? —bit.ly/3JeBlY5
1
247
Jun 11
Thurs news: Employers drop GLP-1 weight loss drug coverage as use surges. J&J adds rare disease wAIHA to Imaavy's potential uses. Takeda’s $4B TYK2 drug tops BMS’ Sotyktu in head-to-head. Novartis gets win for another Avidity muscular dystrophy ADC. —bit.ly/3JeBlY5
1
1
180
Jun 10
Wed news: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon. Novartis sticks 2nd deal with molecular glue biotech Orionis. Lilly’s $25B M&A spree captures half of pharma’s 2026 capacity. Sanofi terminates Phase III CIDP trial. —bit.ly/3JeBlY5
1
263
Jun 9
Tue news: GSK buying cancer drugmaker Nuvalent for $10.6B. Novo’s Wegovy pill hits 3M prescription milestone. Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval. Merck and Gilead have HIV win and cancer stumble. —bit.ly/3JeBlY5
1
200
Jun 8
Mon news: JNJ to acquire degrader antibody firm Firefly for up to $1B. Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset. BI obesity bet delivers ‘less competitive’ weight reduction. Roche doubles down on BTK with $2.3bn Nurix deal. —bit.ly/3JeBlY5
228
Jun 5
Fri news: Lilly and Novo face off at ADA 2026 as others seek to compete in obesity. Roche chairman likens US tariff policy to 'blackmail'. Biogen’s salanersen gains FDA breakthrough therapy for SMA. SCOTUS backs generic firm Hikma in skinny label dispute. —bit.ly/3JeBlY5
180
Jun 4
Thurs news: GLP-1s may help many types of cancer. Argenx’s Vyvgart shows durability in myositis and Sjögren’s. Pharma’s 10 most interesting booths at ASCO. House bill aims to crack down on China biotech deals. —bit.ly/3JeBlY5
274
Jun 3
Wed news: Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B. ASCO’s biggest winners showcased a new era of cancer innovation. Cigna drops coverage of GLP-1 obesity drugs for its own employees. Medtronic sees best revenue growth in 10 years. —bit.ly/3JeBlY5
182
Jun 2
Tue news: ASCO: Takeda touts ‘tremendous potential’ of Innovent’s bispecific. Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off. Merck continues NJ cuts, laying off 88. Stryker launches new small bone power tool for ortho procedures. —bit.ly/3JeBlY5
283
Jun 1
Mon news: ASCO: AZ's Imfinzi, Imjudo duo shines in early stage liver cancer. Moderna partners with CEPI on Ebola vaccine efforts. J&J breaks the prostate cancer treatment mold with fresh Erleada win. Lilly’s Verzenio gives hope of liposarcoma treatment. —bit.ly/3JeBlY5
246
May 29
Fri news: Brand-name drug prices climb after launch in US, fall abroad. ASCO: Lilly debuts ‘strong’ bladder cancer data. AZ posts subgroup data behind pitch for rare disease approval. Pfizer, Innovent strike $10B cancer drug deal. —bit.ly/3JeBlY5
1
228
May 28
Thurs news: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer. Biopharma job searches often take at least 6 months. CVS brings back coverage for Lilly's obesity drug Zepbound. GSK hails 'unprecedented' cure rates with hep B drug. —bit.ly/3JeBlY5
246
May 27
Wed news: Eli Lilly wins argument over Noom’s GLP-1 dosing claims. JNJ New Jersey layoffs. Olympus expands in cancer tech with $270M buy of BioProtect. FDA delays verdict on AZ breast cancer drug. —bit.ly/3JeBlY5
1
373
May 22
Fri news: AbbVie, Novartis slash US headcount. Moderna mRNA flu shot faces FDA adcomm. Intuitive readies 100 updates and improvements for da Vinci 5. Who’s winning pharma’s innovation race? —bit.ly/3JeBlY5
387
May 21
Thurs news: Lilly’s triple-agonist shows 28.3% weightloss. In Alzheimer’s, Bristol Myers sees big promise beyond amyloid. 3 big shifts for the GLP-1 market. Guardant wins FDA approval for updated liquid biopsy. —bit.ly/3JeBlY5
1
330
May 20
Wed news: Lilly buying DNA delivery biotech Engage. AbbVie’s Skyrizi bested by UCB drug in psoriatic arthritis. BMS going all in on Anthropic’s Claude. Medtronic plans to buy SPR Therapeutics to expand pain treatment options. —bit.ly/3JeBlY5
400
May 19
Tue news: SCOTUS declines to hear IRA challenges from Novo, AZ and more. Merck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial. Boston Sci buys $1.5B stake in TAVR developer MiRus. Jury finds Takeda liable in pay-for-delay lawsuit. —bit.ly/3JeBlY5
297
May 18
Mon news: Supreme Court turns away Lilly’s challenge to whistleblower law. Merck scores in endometrial cancer trial. AZ hypertension approval. FDA approves Enhertu for two HER2-positive early breast cancer indications. —bit.ly/3JeBlY5
256